RE: Next Tuesday21 Apr 2023 10:08
gmcc I would fully agree with you regarding FHCC especially that they are evaluating Therapeutic Activity
Full Title
A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients with Locally Advanced or Metastatic Selected Solid Tumours